Livagen
A Russian liver bioregulator run in 10 to 20 day courses a few times a year. Cheap, gentle, animal-only evidence; a tune-up, not a fix.
What it is
Livagen is one of the Khavinson bioregulators, a four-amino-acid fragment aimed at the liver, run as a 10 to 20 day course and then put away for months. People use it as a liver tune-up two or three times a year. The evidence is animal and cell work from one institute, so expect subtle, not dramatic.
The people who run Livagen are already doing the bioregulator thing: Epitalon in the spring, Pinealon for the brain, and a liver course alongside. Others reach for it after a hard stretch of drinking, a long run of medications, or a liver enzyme result that came back a little high and a doctor who said 'watch it.' It is Lys-Glu-Asp-Ala, the liver-targeted member of the family from the St. Petersburg Institute of Bioregulation and Gerontology, and the claim is that it nudges aging liver cells back toward younger patterns of enzyme production and repair. It is not a drug for liver disease and it will not undo a drinking habit.
What you notice: very little, and that is the honest answer. There is no acute feeling from a shot. People who like it report better energy and digestion over the course and a cleaner enzyme panel at the next check, and the only way to know whether it did anything is a before-and-after blood test. It will not fix fatty liver on its own, it will not lower enzymes that are high because of something you are still doing, and ten days is not long enough for any visible change in how you look or feel. Think of it as something you do a couple of times a year, like changing the oil, and judge it on the lab work.
How people run it: 100 to 400 mcg subQ once a day for 10 to 20 days (up to 30), then nothing for a few months, two or three courses a year. The gap is not because it wears off: the effect is meant to carry on for months after a course, so the exact spacing is up to you, and your liver panel is the better guide to when to repeat. 200 mcg for ten days is the convention that keeps showing up in the Russian protocols. No ramp, no timing rules, no food rules. The cost reality is odd: a 20 mg vial is 100 doses at 200 mcg, enough for ten courses, but the mixed solution only lasts three to four weeks, so you will use 2 to 4 mg of it and bin the rest. Mix only part of the vial if you can, or accept that a vial is a one-course purchase. Ignore the protocols online pushing 2000 mcg a day for months; they overshoot the research by ten times and buy nothing but waste.
Evidence: animal and cell work, essentially all from the institute that invented it. In old rats it moved liver and digestive enzyme activity back toward younger patterns; in cell work it reactivated genes that aging tissue switches off, and it blocks an enzyme that breaks down enkephalins, your body's own pain and calm signals. There are no human studies of Livagen at all, which means the safety profile in people is unknown rather than reassuring. It is not approved as a medicine anywhere.
Skip it if you have actual liver disease; that is a doctor's job, and NAC or TUDCA are cheaper, better-studied liver supports with human data. Skip it if you want something you can feel. If your interest is the bioregulator family rather than the liver specifically, Cartalax for joints or Vesugen for blood vessels have the same evidence profile and a target you might notice. Ovagen is the one people pair with Livagen for a broader liver-and-gut course.
What people use it for
Liver enzymes in old animals
Early daysIn aged rats, Livagen shifted liver detox enzyme activity (the cytochrome P450 and glutathione systems) and digestive enzyme output back toward the patterns of young animals. The studies are small, from a single institute, and have not been repeated elsewhere. That is the whole basis for the 'liver tune-up' use.
Switching aged genes back on
Early daysIn cell work on tissue from elderly donors, Livagen loosened tightly packed chromatin and reactivated genes that aging shuts down. Interesting mechanism, the same one claimed for Epitalon and the other bioregulators, and a long way from showing that anything changes in a living person.
Pain and calm signaling
Early daysLivagen blocks an enzyme that breaks down enkephalins, the body's own opioid-like calming peptides, without touching opioid receptors itself. That might explain the calmer, easier feeling some users describe during a course. It is a lab finding, not something anyone has measured in people.
Human use
Early daysThere are no published human studies of Livagen, not even small ones, so its safety profile in people is unknown. The bioregulator family has decades of use in Russia, mostly as the older tissue extracts rather than the synthetic peptides, and that is the only human track record you can point to.
How people use it
Safety, in brief
Things people sometimes notice
- A small red spot or itch at the injection site
- Nothing you can feel, which is the normal experience
- A calmer, easier feeling during the course for some, possibly from the enkephalin effect
- No change on labs, which is also common
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology
- Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people
- Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum